Related by context. All words. (Click for frequent words.) 74 EGFR mutation 72 FLT3 71 T#I [002] 71 epithelial tumors 71 BRAF V#E mutation 71 EGFR mutations 71 EGFR inhibitors 70 HER2/neu 70 WT1 70 TTR gene 70 K ras mutations 69 basal cell nevus syndrome 69 KRAS mutation 69 neuroblastoma tumors 69 T#I mutation 69 prostate cancer CaP 69 KIT mutations 69 Her2/neu 69 TNFa 68 BRAF mutations 68 trastuzumab Herceptin ® 68 estrogen receptor ER 68 EpCAM 68 KRAS mutations 68 GBM tumors 68 EGFR activating mutations 68 cyclin E 68 CLL cells 67 GPNMB 67 ERBB2 67 Stat5 67 BRAF gene 67 BCR ABL 67 MAPK pathway 67 SOD1 gene 67 Epstein Barr virus EBV 67 EGFRvIII 67 B7 H3 67 castration resistant prostate cancer 67 vimentin 67 HER2 receptor 67 HER2 overexpression 67 hypermethylation 66 activating mutations 66 IGF 1R 66 EphA2 66 PKCi 66 colorectal carcinoma 66 mutated K ras 66 HAAH 66 NSCLC tumors 66 AAV2 66 IGF IR 66 tyrosine kinase inhibitors 66 flavopiridol 66 EGFR expression 66 Her2 66 EGF receptor 66 EGFR protein 66 Epidermal Growth Factor Receptor 66 imatinib Gleevec 65 mutated BRAF gene 65 breast cancer subtypes 65 diagnostic biomarker 65 olaparib 65 PCa 65 clusterin 65 Akt activation 65 gastrointestinal stromal tumors GISTs 65 HER-2/neu 65 MAGE A3 65 carcinoembryonic antigen 65 K ras 65 p# mutation 65 oxysterols 65 ADPKD 65 LHRH 65 LRP6 65 advanced adenomas 65 CYT# potent vascular disrupting 65 mutant BRAF 65 ABCB1 65 FUS1 65 PDGFR 65 liver metastases 65 NKG2D 65 Enzastaurin 65 glioblastoma cells 65 virulence genes 65 NS4A 65 autoantibodies 65 p# mutations 65 MGUS 65 M#V mutation 65 metastatic tumors 65 malignant transformation 65 mesotheliomas 65 serous ovarian cancer 65 P selectin 65 A3 adenosine receptor 64 interferon IFN 64 PTPN# 64 BRAF V#E 64 MUC1 * 64 untreated metastatic melanoma 64 proto oncogene 64 lung adenocarcinoma 64 PKM2 64 HER2 expression 64 Gleevec resistant 64 MUC1 64 pCR 64 hedgehog pathway 64 PTEN mutations 64 FGFR2 64 cervical neoplasia 64 androgen receptor AR 64 IGFBP2 64 susceptibility gene 64 CXCL5 64 BCR ABL mutations 64 Wnt signaling pathway 64 EGF receptors 64 mCRC patients 64 causal variants 64 prognostic markers 64 TLR3 64 ERCC1 64 breast carcinomas 64 gastrointestinal stromal tumors GIST 64 p# activation 64 ADAMTS# 64 prognostic marker 64 multidrug resistance 64 endostatin 64 TAp# 64 N. gonorrhoeae 64 CXCR4 64 GISTs 64 carcinoembryonic antigen CEA 64 mesothelin 64 sCJD 64 CD# molecule 64 receptor tyrosine kinase inhibitor 64 hepatocellular carcinoma HCC 64 EGFR 64 AGTR1 64 glioma cells 64 sarcosine 64 metastatic lesions 64 Immunohistochemical analysis 64 germline mutation 64 oncoproteins 64 EGFr 64 glycosylated 64 ZNF# 64 MYCN amplification 64 promoter methylation 64 herpesviruses 64 C. pneumoniae 64 PPARγ 64 immunocompetent 64 EGFR tyrosine kinase inhibitors 64 pancreatic adenocarcinoma 63 DFMO 63 KRAS oncogene 63 eIF 4E 63 metastatic melanomas 63 CCX# 63 NPM1 63 N Myc 63 pDCs 63 EGFR gene 63 micrometastases 63 tumor antigen 63 ErbB2 positive 63 neuroendocrine cancers 63 EBV infection 63 HDAC inhibitors 63 gastric adenocarcinoma 63 tumor biopsies 63 breast carcinoma 63 SMAD4 63 HER2 neu 63 MET amplification 63 nucleoside analogues 63 Factor Receptor 63 atherosclerotic lesions 63 colorectal tumors 63 chemopreventive agent 63 histone deacetylases 63 ErbB2 63 TNFalpha 63 mutated KRAS gene 63 IDH mutations 63 familial ALS 63 myeloma cells 63 RRM1 63 MDM2 63 CXCR7 63 JAK2 63 E. faecalis 63 hepatoma 63 VEGF receptor 63 renal cell carcinomas 63 erlotinib Tarceva ® 63 PARP inhibitor 63 Clusterin 63 recurrent glioblastoma multiforme 63 BRCA1 mutation 63 cMET 63 PECAM 1 63 protein kinase inhibitor 63 myelofibrosis polycythemia vera 63 CD# expression [001] 63 prostate carcinoma 63 PTP 1B 63 immunohistochemical staining 63 alkylating agent 63 cyclin D1 63 genetic polymorphisms 63 poorer prognosis 63 alkylating agents 63 basal cell carcinoma BCC 63 PARP inhibition 63 gene amplification 63 JAK2 mutation 63 node metastases 63 imatinib resistance 63 osteosarcomas 63 hypermethylated 63 activated lymphocytes 63 glioblastoma tumors 63 decitabine 63 Aurora kinase 63 Bcr Abl 63 cisplatin resistant 63 prostate adenocarcinoma 63 molecularly targeted 63 pertuzumab 63 Helicobacter pylori H. pylori 63 chemokine receptor 63 contralateral breast 63 STAT3 63 latent tuberculosis infection 63 metastatic lymph nodes 63 AT1R 63 caveolin 1 63 Zolinza 63 Epstein Barr Virus EBV 63 breast cancer metastasis 63 PC# cells 63 peptide antigens 63 transgenic rats 63 E#F# 63 SPINK1 63 HBeAg negative 63 synovial tissue 63 splice variants 63 taxane chemotherapy 63 activin 63 elevated CRP 63 trastuzumab Herceptin 63 renal tumors 63 leukemic stem cells 63 pRb 63 C1q 63 tumor cells 63 CDK inhibitor 63 EGFR receptor 63 imatinib therapy 63 CagA 63 GSTP1 63 precursor lesions 63 melanoma tumors 63 HBsAg 63 hypereosinophilic syndrome 63 S#A# [002] 62 axillary lymph nodes 62 FGFR1 62 Ras pathway 62 JAK inhibitors 62 HER2 positive metastatic breast 62 XmAb# 62 OGG1 62 MMP inhibitors 62 myeloproliferative diseases 62 P#X# 62 predictive biomarkers 62 K RAS 62 premalignant lesions 62 molecular abnormalities 62 estrogen receptor 62 Trastuzumab 62 metastatic RCC 62 choroidal neovascularization 62 epithelial cancers 62 MEK ERK 62 immunohistochemical 62 neuropilin 62 hematopoietic cells 62 Hurthle cell 62 FGFR4 62 EGFR pathway 62 invasive carcinoma 62 multiple myeloma MM 62 mTOR inhibitors 62 TOP2A 62 familial pancreatic cancer 62 constitutively active 62 thymidylate synthase 62 TGFBR1 * 6A 62 PARP inhibitors 62 HPV# 62 TGF ß 62 SSc 62 #F FDG PET 62 castrate resistant 62 NKX#.# 62 ERK signaling 62 CD#c 62 JAK3 62 somatostatin receptors 62 apoptotic pathway 62 narcolepsy cataplexy 62 molecular biomarkers 62 IDH1 mutation 62 bleomycin 62 Ceflatonin 62 survivin 62 CCR7 62 rheumatoid factor 62 CD# [002] 62 HGPIN 62 CDK4 62 CIN2 + 62 urothelium 62 KRAS status 62 NAbs 62 malignant prostate 62 huC# DM4 62 ALK inhibitors 62 ApoE4 62 predictive biomarker 62 MSH2 62 adenoma 62 H pylori 62 Notch receptors 62 adenoviral 62 Li Fraumeni 62 CCR2 62 premalignant 62 IL#B 62 microRNA expression 62 PI3K Akt 62 Hedgehog pathway 62 selective inhibitors 62 nonmelanoma skin cancers 62 Squamous 62 NF kB pathway 62 CCR9 62 phosphate S1P 62 leukaemias 62 CBLC# 62 LRAT 62 tumorigenicity 62 AEG# 62 pegylated liposomal doxorubicin 62 chromosomal rearrangement 62 genetic loci 62 SERMs 62 lung metastases 62 K#R [002] 62 pulmonary metastases 62 gemcitabine Gemzar 62 IgA deficiency 62 iNOS 62 SIRT2 62 SOD1 62 serum antibodies 62 HER2 gene 62 MGMT gene 62 miRNA genes 62 myeloproliferative disorders 62 VEGFR2 62 AMN# [001] 62 IGFBP 3 62 hCG beta 62 Fas ligand 62 EZH2 62 Abeta# 62 pan HDAC inhibitor 62 intravenous bisphosphonates 62 malignant lymphomas 62 IMA# 62 HCV replication 62 Haptoglobin 62 NNRTI resistance 62 renal fibrosis 62 malignant nodules 62 PIK3CA 62 azacytidine 62 alvespimycin 62 uPAR 62 mRCC 62 GSTM1 62 anticancer therapies 62 refractory chronic myeloid 62 bevacizumab Avastin ® 62 HER2 positive tumors 62 transgenic mouse model 62 hepatocellular carcinoma 62 Vpu 62 KRAS gene 62 IgG1 antibody 62 MLH1 62 histologically 62 chronic eosinophilic leukemia 62 invasive ductal 62 topoisomerase 62 PKC beta 62 genotypic resistance 62 transgene expression 62 ALK mutations 62 Xanafide 62 HER2 positive cancers 62 chlamydial 62 nonsense mutations 62 bone metastasis 62 missense mutation 62 CD# protein 62 rhIL 7 62 prostate cancer PCa 62 autoantibody 62 VIPR2 62 antiangiogenic 62 CD# receptor 62 ADAM# 61 druggable targets 61 small molecule inhibitors 61 transthyretin 61 superficial bladder cancer 61 HIV HCV coinfected 61 oncoprotein 61 pyruvate kinase 61 microRNA miR 61 complete cytogenetic response 61 antitumor 61 differentiated thyroid 61 IFN beta 61 p#HER# 61 malignant lesions 61 prognostic indicator 61 alkaline phosphatase ALP 61 latent TB infection 61 effector function 61 preclinically 61 gefitinib Iressa 61 microglial cells 61 OHR/AVR# 61 gastrointestinal stromal tumors 61 tumor necrosis 61 colorectal neoplasms 61 HQK 61 lung metastasis 61 chlamydial infection 61 Leukemias 61 secretory pathway 61 syngeneic 61 suppressor gene 61 FLT3 mutations 61 androgen independent 61 XL# inhibits 61 FOXP3 61 prostate cancer CRPC 61 PI3K inhibitors 61 PAR1 61 c MET 61 pro angiogenic 61 surface glycoprotein 61 germline mutations 61 gene rearrangements 61 metastatic malignant melanoma 61 tarenflurbil 61 skeletal metastases 61 cytokeratin 61 Hepatocellular Carcinoma HCC 61 virulence determinants 61 PI3 kinase 61 anti angiogenic therapy 61 IDH1 61 INCB# [003] 61 osteopontin 61 tumor suppressor protein 61 cathepsins 61 gastric cancers 61 relapsed ALL 61 ERK1 2 61 xenograft models 61 FGFR3 61 trans retinoic acid 61 VEGF inhibitors 61 oral prodrug 61 antitumor efficacy 61 pre malignant lesions 61 CD# monoclonal antibody 61 NFkB 61 TMEM#B 61 serum biomarkers 61 beta1 integrin 61 depsipeptide 61 Wwox 61 inhibit angiogenesis 61 Imatinib 61 granzyme B 61 HBx 61 somatic mutations 61 KIF6 gene 61 miR #a [001] 61 erlotinib Tarceva 61 KRAS wild 61 mtDNA mutations 61 thalidomide Thalomid 61 thyroglobulin 61 Alemtuzumab 61 NPM1 mutation 61 recurrent NSCLC 61 histologic diagnosis 61 colon tumors 61 Protein Kinase C 61 metachronous 61 tumoral 61 neoplastic cells 61 microdeletions 61 JAK2 enzyme 61 antisense inhibition 61 standard chemotherapy regimens 61 FasL 61 TGF β 61 metastatic prostate 61 PI3K AKT 61 nephrotoxicity 61 Cervista HPV HR 61 leukemic cells 61 microsatellite instability 61 GRN# 61 PI3K pathway 61 BRCA2 mutation 61 Prox1 61 metastatic neuroendocrine tumors 61 MGd 61 nodal metastasis 61 HER2 amplification 61 lung carcinomas 61 CCR3 61 HbF 61 pharmacologic intervention 61 thyrotropin levels 61 SGS# 61 hTERT 61 monoclonal anti 61 DHFR 61 BRAF V# mutation 61 C5aR 61 potent inhibition 61 paricalcitol 61 NFκB 61 BCR ABL protein 61 CTLA 4 61 cervical lymph nodes 61 anti angiogenic agent 61 immunohistochemical analysis 61 TNF α 61 HNSCC 61 Symadex 61 hepatocellular carcinomas 61 cytotoxin 61 serotonin receptor 61 colon carcinoma 61 HER2 receptors 61 metastatic gastric 61 GIST tumors 61 PBMCs 61 RANKL 61 Naive Patients 61 systemically administered 61 CDH1 61 elacytarabine 61 PROCHYMAL 61 MUC1 protein 61 TCF#L# 61 GRP# 61 neurotrophic 61 potently inhibited 61 HCV antibody 61 mutant SOD1 61 EGFR HER2 61 antiproliferative effects 61 HuLuc# 61 EGFR TKIs 61 GPR# [002] 61 thyroid hormone receptor 61 engineered RAP peptides 61 axillary nodes 61 bronchial epithelial cells 61 cervical lesions 61 anti angiogenic drugs 61 HBeAg 61 anaplastic lymphoma kinase 61 estrogen receptor alpha 61 lymphoid 61 cisplatin chemotherapy 61 colorectal carcinomas 61 PhG alpha 1 61 CXCR4 receptor 61 sporadic ALS 61 neuroblastoma cells 61 ovarian carcinoma 61 CYP#C# [001] 61 extramedullary 61 BCL#A 61 #q# deletion 61 PTP1B 61 abacavir Ziagen 61 Lp PLA 2 61 presymptomatic 61 alpha folate receptor 61 enzastaurin 61 miR #a [002] 61 CMV infections 61 Bortezomib 61 N cadherin 61 immunological responses 61 BRAF protein 61 distant metastases 61 lobular carcinoma 61 leukaemic stem cells 61 downregulated 61 ZD# [001] 61 luteinizing hormone releasing 61 UGT#A# 61 hematological cancers 61 TGF ß1 61 endoglin 61 T2DM 61 dasatinib 61 cellular pathways 61 TRAIL induced apoptosis 61 hormone receptor positive 61 PDE#A 61 Estrogen Receptor 61 raltegravir 61 LRP5 61 EGFR mutant 61 Lymph node 61 PTEN gene 61 GAP #B# 61 DLC1 61 BRCA mutation 61 vWF 61 hepatitis C virus 60 mitochondrial toxicity 60 IgG antibodies 60 TNFα 60 chemosensitivity 60 HER3 60 molecular subtypes 60 gefitinib 60 CCR5 antagonist 60 genetic variants associated 60 leukemia AML 60 humanized antibody 60 Ki# 60 HLA B# 60 E selectin 60 S/GSK# 60 receptor molecule 60 epigenetic markers 60 neoadjuvant chemotherapy 60 mammary cells 60 metastatic malignant 60 carcinoids 60 EGFR TKI 60 nucleoside analogs 60 c myc 60 benign moles 60 Virulizin ® 60 signaling cascades 60 colonic mucosa 60 rifamycins 60 CB2 receptor 60 chemokine receptors 60 c KIT 60 leflunomide 60 cystatin C 60 Pralatrexate 60 selective antagonists 60 #HT#A 60 leukemic cell 60 EUS FNA 60 hA# 60 ENMD # 60 immunomodulatory therapy 60 OncoVEX GM CSF 60 miR #b [002] 60 LDL receptor 60 selective modulator 60 uveal melanoma 60 mRNA transcripts 60 HCV infection 60 gene polymorphisms 60 effector functions 60 mutant p# 60 interferon gamma 60 c MYC 60 SIRT1 gene 60 tumors 60 V#F 60 histological subtype 60 primary cilia 60 CD# CD# 60 prognostic factor 60 NF1 60 prostate epithelial cells 60 soluble receptor 60 intestinal metaplasia 60 Tarvacin 60 Akt1 60 tyrosine kinase inhibitor 60 p# biomarker 60 CanAg 60 metastatic renal cell carcinoma 60 APOE allele 60 Leishmania parasite 60 CYP #D# 60 bladder carcinoma 60 Aplidin 60 motor neuron degeneration 60 hormone receptor negative 60 induce apoptosis 60 T#M 60 prospectively defined 60 IL 1ß 60 bicalutamide 60 TET2 60 gastrin 60 clonogenic 60 tumor vasculature 60 adenomatous polyps 60 LHRH agonists 60 histopathologic examination 60 RAR beta 60 tryptase 60 breast epithelial cells 60 thyrotropin 60 CYP#D# 60 platelet reactivity 60 targeting CD# 60 receptor tyrosine kinase 60 microglial 60 renal carcinoma 60 HepG2 cells 60 DNA methylation patterns 60 commonly mutated genes 60 enzymatic activity 60 MIF protein 60 d4T stavudine Zerit 60 sortilin 60 gut mucosa 60 ritonavir boosted 60 gamma secretase inhibitor 60 MALT lymphoma 60 BRCA mutations 60 IFRD1 60 situ LCIS 60 MEFs 60 milatuzumab 60 bcl 2 60 adenocarcinomas 60 SNP rs# [001] 60 nanomolar 60 protein tyrosine phosphatase 1B 60 histone deacetylase inhibitors 60 TPMT 60 riociguat 60 situ CIS 60 DEAR1 60 Myelodysplastic Syndrome MDS 60 IL #R 60 p# MAPK 60 TGF alpha 60 multi kinase inhibitor 60 estrogen receptors 60 selective inhibition 60 antiangiogenesis 60 miRs 60 colorectal liver metastases 60 metastatic colorectal carcinoma 60 EphB4 60 FTLD 60 panobinostat 60 atypical hyperplasia 60 mGlu2 3 60 amyloid deposits 60 leukemia ALL 60 calcineurin 60 GATA3 60 adhesion molecule 60 Olaparib 60 seliciclib 60 Leydig cell 60 antisense inhibitors 60 cAMP signaling 60 radioiodine therapy 60 DXL# 60 IFN gamma 60 missense mutations 60 anticancer therapy 60 TNF blocker therapy 60 investigational humanized monoclonal antibody 60 HER2 ErbB2 60 fluoroquinolone resistance 60 MTHFR 60 HAART regimens 60 p tau 60 HER2 positive 60 gastrointestinal stromal tumor GIST 60 protein tyrosine phosphatase 60 MAP kinase 60 carcinoid 60 macrophage colony stimulating 60 CIMZIA ™ 60 mutant proteins 60 nonalcoholic steatohepatitis NASH 60 neovascularization 60 HCV infected 60 erythropoiesis 60 DGAT1 60 CA4P 60 small molecule activators 60 NOMID 60 mGluR 60 ELISpot 60 INCB# [001] 60 serine protease 60 microglial activation 60 specific antigen 60 monocytic 60 non nucleoside 60 Traficet EN 60 mucosal healing 60 gene loci 60 nucleoside analog 60 K#N 60 complete remissions 60 retinoic acid receptor 60 IgG1 60 IRAK1 60 inherited predisposition 60 Pharmacokinetics PK 60 sarcomatoid 60 catenin 60 antiangiogenic therapy 60 anaplastic lymphoma kinase ALK 60 IL 1β 60 nonsmall cell lung cancer 60 grade cervical intraepithelial 60 p#INK#a 60 Epratuzumab 60 Flt3 60 lymph node metastases 60 mucinous 60 mRNA expression 60 peripheral blood mononuclear 60 TGF beta pathway 60 synovial cells 60 axillary lymph node 60 bevacizumab Avastin 60 proteolytic cleavage 60 hypoxic tumors 60 plasminogen 60 mutational status 60 imatinib 60 peritoneal carcinomatosis 60 xenograft tumors 60 neovascular 60 tumor xenografts 60 activating mutation 60 lactate dehydrogenase LDH 60 metastatic cancers 60 leukemia CLL 60 distant metastasis 60 chronic myeloid leukemia CML 60 cediranib 60 cytostatic 60 HG PIN 60 HAART regimen 60 obstructive coronary artery 60 Dasatinib 60 squamous cell lung cancer 60 CC genotype 60 Gefitinib 60 independent prognostic marker 60 B CLL 60 APOE4 60 mitochondrial disorders 60 EGFR signaling 60 androgen receptor 60 synthetic retinoid 60 cell signaling pathways 60 miglustat 60 CD#b 60 mutant allele 60 NPM1 mutations 60 ARF1 60 angiogenesis inhibitor 60 intestinal polyps 60 Smad7 60 cancer mCRC 60 myeloid cells 60 VAPRISOL 60 Notch1 60 lymphoid cells 60 alpha#beta# integrin 60 IgG antibody 60 genetic aberrations 60 EGFR mutation status 60 telomere lengths 60 TNF alpha antagonist 60 HCV protease 60 Vorinostat 60 CD4 + T lymphocytes 60 deacetylase inhibitors 60 OMP #M# 60 Sjögren syndrome 60 PsA 60 MyVax R 60 M. pneumoniae 60 bispecific antibody 60 P. gingivalis 60 prognostic significance 60 overexpression 60 IL 1beta 60 erythropoietic 60 dexpramipexole 60 castrate resistant prostate cancer 60 gastric carcinoma 60 tyrosine phosphorylation 60 haematopoietic 60 malignant pleural mesothelioma 60 mGluR2 NAM 60 ErbB 60 PCA3 60 Cytotoxic T 60 apoE4 60 immunodeficient 60 nelfinavir 60 myeloperoxidase 60 genetic alteration 60 ocular disorders 60 docetaxel chemotherapy 60 β catenin 60 locoregional recurrence 60 Immunohistochemical staining 60 COX2 60 cytoprotective 59 Jhdm2a 59 Fibroblasts 59 C#Y 59 relapsed leukemia 59 p#NTR 59 Pin1 59 mTOR mammalian target 59 mutated BRCA1 59 APOE ε4 59 chronic lymphocytic leukemia CLL 59 tumors GIST 59 PDGF receptor 59 NRTI 59 chemoresistant 59 metaplasia 59 fibrotic disease 59 PLX# 59 LY# [003] 59 galiximab 59 kidney urologic 59 elevated triglyceride levels 59 RAS mutations 59 lenalidomide Revlimid R 59 uPA 59 immunostaining 59 JAK2 V#F 59 HLA DR 59 antibody MAb 59 CaM kinase II 59 ERa 59 canakinumab 59 SATB1 59 glucocorticoid receptors